Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 6.55% is 648% above its 5-year average of -1.19%, near the high end of its 5-year range (-10.18%–6.55%).
As of the fiscal period ended Tuesday, June 30, 2026. 38.62% above its 12-month average of 4.72%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 6.55%.
RETURN ON EQUITY (ROE)
6.55%
RETURN ON EQUITY (ROE) AVG TTM
4.72%
RETURN ON EQUITY (ROE) AVG 3Y
1.97%
RETURN ON EQUITY (ROE) AVG 5Y
-1.19%
RETURN ON EQUITY (ROE) AVG 10Y
-3.59%
RETURN ON EQUITY (ROE) AVG 15Y
-31.58%
RETURN ON EQUITY (ROE) AVG 20Y
-44.93%
CURRENT VS TTM AVG
+38.62%
CURRENT VS 3Y AVG
+232.31%
CURRENT VS 5Y AVG
+648.36%
CURRENT VS 10Y AVG
+282.46%
CURRENT VS 15Y AVG
+120.73%
CURRENT VS 20Y AVG
+114.57%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+115.58%
vs the sector median at left
Vericel Corporation
Market Cap
$2.06B
Return on Equity (ROE)
6.55%
TTM Avg
4.72%
3Y Avg
1.97%
5Y Avg
-1.19%
Market Cap
$2.06B
Return on Equity (ROE)
-58.45%
TTM Avg
-43.81%
3Y Avg
-43.57%
5Y Avg
-51.47%
Market Cap
$2.07B
Return on Equity (ROE)
-42.07%
TTM Avg
-35.11%
3Y Avg
-34.40%
5Y Avg
-30.49%
Market Cap
$2.03B
Return on Equity (ROE)
N/A
TTM Avg
-101.38%
3Y Avg
-17.29%
5Y Avg
175.33%
Market Cap
$2.03B
Return on Equity (ROE)
17.35%
TTM Avg
12.11%
3Y Avg
10.87%
5Y Avg
16.24%
Market Cap
$2.08B
Return on Equity (ROE)
-98.56%
TTM Avg
-37.96%
3Y Avg
-71.53%
5Y Avg
-45.53%
Market Cap
$2.03B
Return on Equity (ROE)
N/A
TTM Avg
793.39%
3Y Avg
466.61%
5Y Avg
69.31%
Market Cap
$2.03B
Return on Equity (ROE)
-16.25%
TTM Avg
-99.56%
3Y Avg
-48.75%
5Y Avg
-32.00%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vericel Corporation (VCEL) | $2.06B | 6.55% | 4.72% | 1.97% | -1.19% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -58.45% | -43.81% | -43.57% | -51.47% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | -42.07% | -35.11% | -34.40% | -30.49% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | N/A | -101.38% | -17.29% | 175.33% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 17.35% | 12.11% | 10.87% | 16.24% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.08B | -98.56% | -37.96% | -71.53% | -45.53% |
| Alvotech (ALVO)vs › | $2.09B | N/A | 23.18% | 49.13% | 48.50% |
| UroGen Pharma Ltd. (URGN)vs › | $2.03B | N/A | 793.39% | 466.61% | 69.31% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.03B | -16.25% | -99.56% | -48.75% | -32.00% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | 51.09% | 25.46% | 0.90% | -9.89% |
ROE
6.5%
ROA
4.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 6.55% |
| 2026-03-31 | 6.02% |
| 2025-12-31 | 4.66% |
| 2025-09-30 | 4.06% |
| 2025-06-30 | 2.32% |
| 2025-03-31 | 1.01% |
| 2024-12-31 | 3.55% |
| 2024-09-30 | 1.38% |
| 2024-06-30 | 0.32% |
| 2024-03-31 | 0.19% |
| 2023-12-31 | -1.41% |
| 2023-09-30 | -5.02% |
| 2023-06-30 | -6.62% |
| 2023-03-31 | -8.82% |
| 2022-12-31 | -8.69% |
| 2022-09-30 | -10.18% |
| 2022-06-30 | -9.41% |
| 2022-03-31 | -6.54% |
| 2021-12-31 | -4.38% |
| 2021-09-30 | 0.14% |
| 2021-06-30 | 5.80% |
| 2021-03-31 | 3.05% |
| 2020-12-31 | 2.13% |
| 2020-09-30 | 0.13% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | -10.44% |
| 2019-12-31 | -8.70% |
| 2019-09-30 | -14.36% |
| 2019-06-30 | -20.85% |
| 2019-03-31 | -3.22% |
| 2018-12-31 | -7.96% |
| 2018-09-30 | -13.86% |
| 2018-06-30 | -19.24% |
| 2018-03-31 | -72.45% |
| 2017-12-31 | -76.69% |
| 2017-09-30 | -142.02% |
| 2017-06-30 | -179.19% |
| 2017-03-31 | -165.72% |
| 2016-12-31 | -79.19% |
| 2016-09-30 | -160.44% |
| 2016-06-30 | -93.65% |
| 2016-03-31 | -78.69% |
| 2015-12-31 | -73.84% |
| 2015-09-30 | -52.25% |
| 2015-06-30 | -53.90% |
| 2015-03-31 | -59.26% |
| 2014-12-31 | -55.89% |
| 2014-09-30 | -54.17% |
| 2014-06-30 | -568.11% |
| 2014-03-31 | -426.45% |
| 2013-12-31 | -401.18% |
| 2013-09-30 | -391.03% |
| 2013-03-31 | -405.50% |
| 2012-12-31 | -309.83% |
| 2010-09-30 | -158.81% |
| 2010-06-30 | -99.65% |
| 2010-03-31 | -73.26% |
| 2009-12-31 | -113.57% |
| 2009-09-30 | -88.81% |
| 2009-06-30 | -92.26% |
| 2009-03-31 | -85.03% |
| 2008-12-31 | -104.74% |
| 2008-09-30 | -95.99% |
| 2008-06-30 | -86.28% |
| 2008-03-31 | -71.20% |
| 2007-12-31 | -59.69% |
| 2007-09-30 | -74.77% |
| 2007-06-30 | -62.28% |
| 2007-03-31 | -52.86% |
| 2006-12-31 | -47.68% |
| 2006-09-30 | -43.69% |
| 2006-06-30 | -38.91% |
| 2006-03-31 | -69.42% |
| 2005-12-31 | -53.88% |
| 2005-09-30 | -42.14% |
| 2005-06-30 | -35.76% |
| 2005-03-31 | -30.93% |
| 2004-12-31 | -43.39% |
| 2004-09-30 | -63.22% |
| 2004-06-30 | -59.56% |
| 2004-03-31 | -90.13% |
| 2003-12-31 | -84.40% |
| 2003-09-30 | -69.61% |
| 2003-06-30 | -82.76% |
| 2003-03-31 | -130.61% |
